A Study to Evaluate the Safety of HS-10506 in Chinese Patients With Insomnia Disorder

NCT07677384 | Not Yet Recruiting Phase 3

• 1 other identifier: HS-10506-303
• Study Type: interventional
• Target: 600
• Locations: 0 countries
• Sites: N/A

Brief Summary

The primary purpose of this open-label phase Ⅲ study is to evaluate the safety of HS-10506 on the incidence and severity of adverse events (AE), serious adverse events (SAE), adverse events of special interest (AESI) in Chinese adult participants with insomnia disorder.

Conditions

Insomnia Disorder

Keywords

Clinical trial; insomnia disorder; open-label; long-term; phase 3

Outcome Measures

Primary Outcomes (3)

• Incidence and severity of adverse events (AE)

  An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

  From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 13 months

• Incidence and severity of serious adverse events (SAE)

  An SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participants and/or may require medical or surgical intervention to prevent one of the outcomes listed above.

  From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 13 months

• Incidence and severity of adverse events of special interest (AESI)

  An AESI (serious or non-serious) is any medical event specific to the investigational product or clinical trial.

  From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 13 months

Secondary Outcomes (11)

• Number of Participants With Clinically Significant Change in hematology

  Baseline, Week 12, Week 24, Week 36, Week 48

• Number of Participants With Clinically Significant Change in clinical chemistry

  Baseline, Week 12, Week 24, Week 36, Week 48

• Number of Participants With Clinically Significant Change in urinalysis

  Baseline, Week 12, Week 24, Week 36, Week 48

• Withdrawal symptoms by Physician Withdrawal Checklist (PWC-20)

  The day after the last administration and at least 7 days after discontinuation of the medication

• Rebound insomnia by subjective sleep onset latency (sSOL) during the follow-up period

  Baseline, Follow-up Period (7-9 days)

Study Arms (1)

HS-10506

EXPERIMENTAL

Participants will receive HS-10506 tablets, orally, once nightly for 4/24/36/48 consecutive weeks.

Drug: HS-10506

Interventions

HS-10506 DRUG

HS-10506 tablet

HS-10506

Eligibility Criteria

• Age: 18 Years - 64 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Participants must be 18 to 65 years of age (inclusive 18, not inclusive 65);
• Participants are required to voluntarily sign the informed consent form;
• Body mass index (BMI): BMI (weight/height2 \[kg/m2\]) must be in the range of 18 to 35 kg/m2 (inclusive);
• For Participants completed Study 301: Participants have completed the Study 301, can potentially benefit from extended treatment with HS-10506 and have no major safety risks according to the investigator's clinical judgment;
• For new Participants: Participants must meet Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-5) criteria for insomnia disorder;
• For new Participants: Participants must have Insomnia Severity Index (ISI) scores≥15 at screening;
• For new Participants: Participants must have an sSOL≥30 minutes, sWASO≥30 minutes, and sTST\<6.5 hours for at least three nights every week within one month prior to screening; and sSOL≥30 minutes, sWASO≥30 minutes, and sTST\<6.5 hours for at least 3 nights from sleep diary in the last 7 consecutive days before the first dose in the open-label treatment period;

You may not qualify if:

• Has received systemic hypnotherapy, cognitive behavioral therapy (CBT), or other non-pharmacological treatments for insomnia in last 4 weeks or have plans during the study;
• Has a risk of suicide according to the Columbia Suicide Severity Rating Scale (C-SSRS), or has a high risk of suicide at the discretion of the investigator;
• Has used any medication that may affect the pharmacokinetics of HS-10506 or GLP-1R-related single/multi-target drugs within the past 2 weeks or 5 half-lives of the medication;
• Has used any medication that may affect sleep-wake function, or any other prohibited central nervous system active medications within 1 week or 5 half-lives of the medication;
• Has a history of drug dependency or abuse within the past 1 year or showed positive in urine drug test at screening;
• Has a history of alcohol abuse within the past 1 year or can't obey the rules of alcohol restriction;
• Has a history of smoking≥10 cigars daily within the past 3 months or can't obey the rules of cigar restriction;
• Has a history of caffeine consumption≥600 mg per day or can't obey the rules of caffeine restriction;
• Has been working across 3 or more time zones or shift work within 2 weeks prior to screening;
• Has taken more than 3 naps per week for\>1 hour each time within the past 2 weeks prior to screening;
• Has any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.
• For Participants completed Study 301: Has been diagnosed with a sleep-wake disorders or sleep-related breathing disorders other than insomnia disorder during Study 301, such as restless legs syndrome, periodic limb movement disorder, circadian rhythm disorder, narcolepsy, rapid eye movement sleep phase (REM) behavioral disorders, and obstructive sleep apnea;
• For Participants completed Study 301: Has been diagnosed with neurodevelopmental retardation, cognitive impairment, epilepsy, schizophrenia, bipolar disorder, hyperthyroidism, cancer, severe cardio-cerebrovascular diseases or respiratory diseases; or current chronic pain that affects sleep, nocturia resulting in frequent need to get out of bed to use the bathroom during the night; or clinically significant and/or unstable neurological, psychiatric, respiratory, cardiovascular, digestive, immunologic, urologic, endocrine diseases during Study 301; or other systemic diseases that are inappropriate for the study;
• For Participants completed Study 301: Previously participated in any clinical trial other than HS-10506-301 within 3 months prior to screening;
• For new Participants: Has history of/current sleep-wake disorders or sleep-related breathing disorders other than insomnia disorder, such as restless legs syndrome, periodic limb movement disorder, circadian rhythm disorder, narcolepsy, rapid eye movement sleep phase (REM) behavioral disorders, and obstructive sleep apnea;

Sponsors & Collaborators

• Jiangsu Hansoh Pharmaceutical Co., Ltd.: lead

MeSH Terms

Conditions

Sleep Initiation and Maintenance Disorders

Condition Hierarchy (Ancestors)

Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Nervous System Diseases; Mental Disorders

Central Study Contacts

Yuping Wang, Principal Investigator

CONTACT

13501186298; wangyuping01@sina.cn

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 8, 2026
• First Posted: June 30, 2026
• Study Start: June 12, 2026
• Primary Completion (Estimated): June 30, 2029
• Study Completion (Estimated): June 30, 2029
• Last Updated: June 30, 2026

Record last verified: 2026-05